Since hematopoietic stem-cells (HSCs) can transform into any type of blood cell, they are currently being used in the treatment of various blood cancers and disorders. These include:
EMERGING THERAPIES WITH CORD TISSUE STEM CELLS
As per Latest draft of “ National Guideline for stem cell Research “ published by the Apex regulatory body of cellular therapy in India ICMR guidelines 2013 and also ICMR draft guideline 2017 it is clearly mentioned
14.1. Banking of Umbilical Cord Blood
UCB is a rich source of CD34+ hematopoietic and mesenchymal (stromal) stemcells. Use of UCB derived HSCs for treatment of various haematological and immunological disorders is currently well established, particularly where an HLAmatched sibling is not available. However, there is a paucity of public funded UCBbanks in India. On the other hand several private UCB banks have come-up, thatengage themselves in promotional advertisements offering storage of cord bloodwith the promise of future therapeutic use. Such advertisements are oftenmisleading for the public and lack comprehensive and accurate information to theconsumer. So far there is no scientific basis for preservation of cord blood forfuture self-use and this practice therefore raises ethical and social concerns.
Link : http://www.icmr.nic.in/